Computational Drug Discovery in Action
Our preclinical pipeline combines peptide chemistry with cutting-edge in-silico methods. All programs are built on validated computational workflows, from target identification through lead optimization.
AXD-001
Lead ProgramOncology — Solid Tumors
Target
Undisclosed peptide target
Lead peptide optimization underway. Target validation complete. Next phase: structure-activity relationship refinement.
DEVELOPMENT STAGE
Hit-to-Lead
AXD-002
Neurodegeneration
Target
Amyloidogenic peptide modulator
Computational screening against target database. Identifying hit series with predicted ADMET properties. Validation pending.
DEVELOPMENT STAGE
Virtual Screening
AXD-003
Inflammatory Disease
Target
Undisclosed peptide target
Target characterization in progress. Bioinformatic analysis complete. Virtual screening pipeline preparation underway.
DEVELOPMENT STAGE
Target Validation
How Our Pipeline Works
Target Identification & Validation
We use computational methods to identify and validate novel peptide targets based on disease biology, biomarker data, and literature mining.
Virtual Screening
Our platform screens billions of peptide-like molecules against validated targets using structure-based and ligand-based computational methods.
Hit-to-Lead Optimization
Computational design of improved analogs with enhanced potency, selectivity, and ADMET properties through iterative de novo design.
Lead Optimization
Final refinement for preclinical candidate selection, including metabolic stability, off-target effects, and in vivo performance prediction.
Interested in collaboration opportunities?
Get in TouchReady to accelerate your drug discovery program?
Whether you're seeking a computational co-development partner, licensing opportunities, or looking to advance a difficult target — let's talk.